Evidence map›Paper›PMID 27657053›Full record

ReviewInternational journal of molecular sciences2016

Protein Kinases and Parkinson's Disease.

Syed Jafar Mehdi, Hector Rosas-Hernandez, Elvis Cuevas, Susan M Lantz, Steven W Barger, Sumit Sarkar, Merle G Paule, Syed F Ali, Syed Z Imam

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Modeling neurodegenerative and neurodevelopmental disorders in theLearning & memory (Cold Spring Harbor, N.Y.) · 2024
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. SNPs rs11240569, rs708727, and rs823156 inInternational journal of molecular sciences · 2019
    Article
  12. Exploring cancer inBrain and behavior · 2018
    Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Syed Jafar MehdiDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. SJMehdi@uams.edu.
Hector Rosas-HernandezDivision of Neurotoxicology, National Center for Toxicological Research/US Food and Drug Administration, Jefferson, AR 72079, USA. Hector.Rosas-Hernandez@fda.hhs.gov.
Elvis CuevasDivision of Neurotoxicology, National Center for Toxicological Research/US Food and Drug Administration, Jefferson, AR 72079, USA. Elvis-Yane.Cuevas-Martinez@fda.hhs.gov.
Susan M LantzDivision of Neurotoxicology, National Center for Toxicological Research/US Food and Drug Administration, Jefferson, AR 72079, USA. Susan.Lantz@fda.hhs.gov.
Steven W BargerDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. BargerStevenW@uams.edu.
Sumit SarkarDivision of Neurotoxicology, National Center for Toxicological Research/US Food and Drug Administration, Jefferson, AR 72079, USA. Sumit.Sarkar@fda.hhs.gov.
Merle G PauleDivision of Neurotoxicology, National Center for Toxicological Research/US Food and Drug Administration, Jefferson, AR 72079, USA. Merle.Paule@fda.hhs.gov.
Syed F AliDivision of Neurotoxicology, National Center for Toxicological Research/US Food and Drug Administration, Jefferson, AR 72079, USA. Syed.Ali@fda.hhs.gov.
Syed Z ImamDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. Syed.Imam@fda.hhs.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, the lack of new drug candidates for the treatment of major neurological disorders such as Parkinson's disease has intensified the search for drugs that can be repurposed or repositioned for such treatment. Typically, the search focuses on drugs that have been approved and are used clinically for other indications. Kinase inhibitors represent a family of popular molecules for the treatment and prevention of various cancers, and have emerged as strong candidates for such repurposing because numerous serine/threonine and tyrosine kinases have been implicated in the pathobiology of Parkinson's disease. This review focuses on various kinase-dependent pathways associated with the expression of Parkinson's disease pathology, and evaluates how inhibitors of these pathways might play a major role as effective therapeutic molecules.

Indexed as

dopaminekinase inhibitorsParkinson’s diseaseserine/threonine kinasetyrosine kinase

Identifiers

PMID27657053
PMCPMC5037850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.